Company: BOLT
Filing Date: 2025-10-02
Form Type: 8-K
Source: 0001193125-25-228293
Chunk: 0

Company: Bolt Biotherapeutics, Inc.
Filing Date: 2025-10-02
Form: 8-K
Item: Item 2.05
Chunk 0
---
Item 2.05 Costs Associated with Exit or Disposal Activities.

On October 1, 2025, Bolt Biotherapeutics, Inc., a Delaware corporation (the “ Company”), implemented a restructuring plan pursuant to which it will reduce overall operating expenses to preserve cash. The restructuring plan includes a reduction of the Company’s current workforce by approximately 20 employees, or approximately 50% of the Company’s workforce. The Company estimates that it will incur aggregate pre-tax charges between approximately $1.5 million to $2.0 million in connection with the reduction-in-force, primarily consisting of severance payments, employee benefits, and related costs. The Company expects that the reduction-in-force will be complete by the end of 2025 and that the associated charges will be recorded in the fourth quarter of 2025. The estimated charges that the Company expects to incur are subject to a number of assumptions, and actual results may differ materially from these estimates. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the restructuring plan.

Item 8.01 Other Events